title: Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma.
abstract: On the basis of the benefits of frontline radiation in early-stage, extranodal natural killer (NK)/T-cell lymphoma (ENKTL), we conducted the trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of gemcitabine, dexamethasone and cisplatin (GDP). Thirty-two patients with newly diagnosed, stage IE to IIE, nasal ENKTL received CCRT (that is, all patients received intensity-modulated radiotherapy 56 Gy and cisplatin 30 mg/m(2) weekly, 3-5 weeks). Three cycles of GDP (gemcitabine 1000 mg/m(2) intravenously (i.v.) on days 1 and 8, dexamethasone 40 mg orally on days 1-4 and cisplatin 75 mg/m(2) i.v. on day 1 (GDP), every 21 days as an outpatient were scheduled after CCRT. All patients completed CCRT, which resulted in 100% response that included 24 complete responses (CRs) and eight partial responses. The CR rate after CCRT was 75.0% (that is, 24 of 32 responses). Twenty-eight of the 32 patients completed the planned three cycles of GDP, whereas four patients did not because they withdrew (n = 1) or because they had an infection (n = 3). The overall response rate and the CR rate were 90.6% (that is, 29 of 32 responses) and 84.4% (that is, 27 of 32 responses), respectively. Only two patient experienced grade 3 toxicity during CCRT (nausea), whereas 13 of the 30 patients experienced grade 4 neutropenia. The estimated 3-year overall survival and progression-free rates were 87.50% and 84.38%, respectively. In conclusion, CCRT followed by GDP chemotherapy can be a feasible and effective treatment strategy for stage IE to IIE nasal ENKTL.
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: Q-H
authors.initials: QH
authors.lastname: Ke
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: S-Q
authors.initials: SQ
authors.lastname: Zhou
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: W
authors.initials: W
authors.lastname: Du
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: G
authors.initials: G
authors.lastname: Liang
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Lei
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: F
authors.initials: F
authors.lastname: Luo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D059248:Chemoradiotherapy; D002945:Cisplatin; D003841:Deoxycytidine / Q000031:analogs & derivatives; D003907:Dexamethasone; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
chemical_list: D003841:Deoxycytidine; D003907:Dexamethasone; D002945:Cisplatin